Literature DB >> 35881275

Hypercoagulability in Cushing's syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols.

Richard A Feelders1, Lynnette K Nieman2.   

Abstract

Cushing's syndrome (CS) is associated with a hypercoagulable state resulting in an increased risk on venous thromboembolism (VTE). In patients with untreated active CS VTE incidence is up to 18-fold higher compared to the general population, whereas after pituitary and adrenal surgery a postoperative VTE risk between 2.6 and 5.6% has been reported. Interestingly, after surgery the VTE risk is not only increased in the first week but also during several months postoperatively. The hypercoagulable state in CS is thought to be caused, at least in part, by an imbalance between activity of pro- and anticoagulant pathways. However, changes in activated partial thromboplastin time and plasma concentrations of pro-and anticoagulant factors are not observed in every CS patient. Only retrospective studies have shown that thromboprophylaxis lowers VTE risk in CS. Future prospective studies should asses the optimal timing, duration and type of thromboprophylaxis in CS to improve VTE-related morbidity and mortality.
© 2022. The Author(s).

Entities:  

Keywords:  Coagulation; Cushing’s syndrome; Fibrinolysis; Thromboprophylaxis; Venous thromboembolism

Year:  2022        PMID: 35881275     DOI: 10.1007/s11102-022-01261-9

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   3.599


  18 in total

1.  The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.

Authors:  R van der Pas; C de Bruin; F W G Leebeek; M P M de Maat; D C Rijken; A M Pereira; J A Romijn; R T Netea-Maier; A R Hermus; P M J Zelissen; F H de Jong; A J van der Lely; W W de Herder; S W J Lamberts; L J Hofland; R A Feelders
Journal:  J Clin Endocrinol Metab       Date:  2012-01-25       Impact factor: 5.958

Review 2.  Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment.

Authors:  R van der Pas; F W G Leebeek; L J Hofland; W W de Herder; R A Feelders
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04       Impact factor: 3.478

3.  Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?

Authors:  Mattia Barbot; Viviana Daidone; Marialuisa Zilio; Nora Albiger; Linda Mazzai; Maria Teresa Sartori; Anna Chiara Frigo; Massimo Scanarini; Luca Denaro; Marco Boscaro; Sandra Casonato; Filippo Ceccato; Carla Scaroni
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

4.  Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN.

Authors:  Elena Valassi; Holger Franz; Thierry Brue; Richard A Feelders; Romana Netea-Maier; Stylianos Tsagarakis; Susan M Webb; Maria Yaneva; Martin Reincke; Michael Droste; Irina Komerdus; Dominique Maiter; Darko Kastelan; Philippe Chanson; Marija Pfeifer; Christian J Strasburger; Miklós Tóth; Olivier Chabre; Michal Krsek; Carmen Fajardo; Marek Bolanowski; Alicia Santos; Peter J Trainer; John A H Wass; Antoine Tabarin
Journal:  Eur J Endocrinol       Date:  2018-02-12       Impact factor: 6.664

5.  Excess Morbidity Persists in Patients With Cushing's Disease During Long-term Remission: A Swedish Nationwide Study.

Authors:  Eleni Papakokkinou; Daniel S Olsson; Dimitrios Chantzichristos; Per Dahlqvist; Elin Segerstedt; Tommy Olsson; Maria Petersson; Katarina Berinder; Sophie Bensing; Charlotte Höybye; Britt Edén-Engström; Pia Burman; Lorenza Bonelli; Cecilia Follin; David Petranek; Eva Marie Erfurth; Jeanette Wahlberg; Bertil Ekman; Anna-Karin Åkerman; Erik Schwarcz; Ing-Liss Bryngelsson; Gudmundur Johannsson; Oskar Ragnarsson
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

6.  A venous thromboembolism risk assessment model for patients with Cushing's syndrome.

Authors:  Marialuisa Zilio; Linda Mazzai; Maria Teresa Sartori; Mattia Barbot; Filippo Ceccato; Viviana Daidone; Alessandra Casonato; Graziella Saggiorato; Franco Noventa; Laura Trementino; Paolo Prandoni; Marco Boscaro; Giorgio Arnaldi; Carla Scaroni
Journal:  Endocrine       Date:  2015-06-26       Impact factor: 3.633

7.  Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery.

Authors:  Luca Manetti; Fausto Bogazzi; Clara Giovannetti; Valentina Raffaelli; Maura Genovesi; Giovanni Pellegrini; Lucia Ruocco; Aldo Iannelli; Enio Martino
Journal:  Eur J Endocrinol       Date:  2010-08-09       Impact factor: 6.664

Review 8.  The coagulant response in sepsis and inflammation.

Authors:  M Levi
Journal:  Hamostaseologie       Date:  2010-01       Impact factor: 1.778

9.  Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome.

Authors:  Marco Boscaro; Nicoletta Sonino; Alessandro Scarda; Luisa Barzon; Francesco Fallo; Maria T Sartori; Giovanni M Patrassi; Antonio Girolami
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

Review 10.  Hypercoagulable state in Cushing's syndrome: a systematic review.

Authors:  Bregje Van Zaane; Erfan Nur; Alessandro Squizzato; Olaf M Dekkers; Marcel Th B Twickler; Eric Fliers; Victor E A Gerdes; Harry R Büller; Dees P M Brandjes
Journal:  J Clin Endocrinol Metab       Date:  2009-05-19       Impact factor: 5.958

View more
  1 in total

1.  Special issue: Cushing's disease update.

Authors:  Maria Fleseriu
Journal:  Pituitary       Date:  2022-08-24       Impact factor: 3.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.